On August 21, Spanish website Intereconomia reported that Amgen would be announcing its acquisition of Alexion Pharmaceuticals in the next few days. Acquired Achillion Pharmaceuticals, the company that began development of two oral factor D inhibitors. No statement in this announcement, including statements that the acquisition is accretive to core EPS, or enhancing to core operating margins should be interpreted to mean that earnings per share or core operating margins of AstraZeneca or Alexion for the current or future financial years would necessarily match or exceed the historical published earnings per share or core operating margins of AstraZeneca or Alexion. Unless otherwise stated: financial information relating to AstraZeneca has been extracted or derived from the audited results for the twelve months ended 12 December 2019; and financial information relating to Alexion has been extracted or derived from the audited results for the twelve months ended 31 December 2019, and the unaudited results for the nine months ended 30 September 2020. The acquisition is a Class 1 transaction for AstraZeneca and as such, will require the approval of its shareholders to comply with the UK Listing Rules. BOSTON--(BUSINESS WIRE)--Jul. Alexion would pay AstraZeneca a fee of up to $1.2 billion if it completes a deal with another buyer. Enhanced revenue growth, operating margin and cash-flow generation. Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia and lysosomal acid lipase deficiency as well as the first and only approved Factor Xa inhibitor reversal agent. The acquisition adds Factor Xa inhibitor reversal agent Andexxa ® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed as Ondexxya ® in Europe, to Alexion’s commercial … Bell ... Kanuma, which Alexion acquired in its acquisition of Synageva, was approved in 2015 to treat lysosomal acid lipase deficiency, a fatal genetic disorder that cause fatty material to build up in blood vessel walls, the liver, and other tissues. Both companies share the same dedication to science and innovation to deliver life-changing medicines. A webinar and conference call for investors and analysts will begin at 2:00 pm UK time today, please join 10-15 minutes prior to the scheduled start time. In December 2020, AstraZeneca agreed to buy Alexion for $175 per share in cash and stock, valuing the Boston-based company at $39 billion. Dec 14, 2020 12:10PM EST Alexion Pharmaceuticals, Inc. ALXN entered into a definitive agreement with U.K.-based pharmaceutical company, AstraZeneca plc AZN, whereby the latter will acquire … Company Secretary By Darcy Jimenez 20 Apr 2021 (Last Updated April 20th, 2021 15:32) AstraZeneca’s proposed $39bn acquisition of rare disease therapy company Alexion Pharmaceuticals has passed a US Federal Trade Commission review. For Media enquiries, Megan Goulart, +18573388634, and for Investor Relations, Chris Stevo, +18573389309. 2, 2020-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the successful completion of its acquisition of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). The acquisition terms provide that Alexion will be liable to pay a break fee of up to $1.2bn to AstraZeneca in certain specified circumstances (including a change of Alexion’s board recommendation or completion of an alternative acquisition). You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. In particular, the information contained in this website does not constitute an offer to sell or otherwise dispose of or any invitation or solicitation of any offer to purchase or subscribe for any securities pursuant to the Transaction or otherwise in any jurisdiction in which such offer or solicitation is unlawful. The acquisition adds Factor Xa inhibitor reversal agent Andexxa ® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed as Ondexxya ® in Europe, to Alexion’s commercial portfolio. ", Ludwig Hantson, Ph.D., Chief Executive Officer, Alexion, said: “For nearly 30 years Alexion has worked to develop and deliver transformative medicines to patients around the world with rare and devastating diseases. Accordingly, in certain instances, the sum or percentage change of the numbers contained in this announcement may not conform precisely with the total figure given. Alexion Pharmaceuticals was acquired by AstraZeneca for $39B on Dec 12, 2020. E.g. Nothing contained in this area of the website should be construed as a profit estimate or profit forecast and no statement in this area of the website should be interpreted to mean that earnings per share of AstraZeneca or Alexion for the current or future financial years would necessarily match or exceed the historical published earnings per share of AstraZeneca or Alexion. AstraZeneca expects to generate significant value from the acquisition by extending Alexion's commercial reach through leveraging AstraZeneca’s global presence and accelerating the development of Alexion's pipeline. ACQUISITION . AstraZeneca shareholders approve Alexion acquisition . More recently, Alexion launched Ultomiris (ravulizumab), a second-generation C5 monoclonal antibody with a more convenient dosing regimen. AstraZeneca on Saturday said it would acquire Alexion Pharmaceuticals for $US39 billion. BOSTON--(BUSINESS WIRE)--Jan. 28, 2020-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced it has completed its acquisition of Achillion Pharmaceuticals, Inc. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION. (ii) Any references to the issued and to be issued ordinary share capital of Alexion are based on: •      the 218,720,567 Alexion Shares referred to in paragraph (i) above; and. Morgan Stanley & Co. International plc (“Morgan Stanley”) and Morgan Stanley Bank International Limited and J.P. Morgan are acting as financial advisors and lead debt financing underwriters. Alexion Pharmaceuticals (NASDAQ:ALXN) has completed its acquisition of Portola Pharmaceuticals (NASDAQ:PTLA), through a tender offer and … In contrast, AstraZeneca's capabilities in genomics, precision medicine and oligonucleotides can be leveraged to develop medicines targeting less-frequent diseases. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that its shareholders have voted to adop The boards of directors of both companies have unanimously approved the acquisition. The deal is expected to price Alexion … AstraZeneca provides this link as a service to website visitors. AstraZeneca intends to establish Boston, Massachusetts, US as its headquarters for rare diseases, capitalising on talent in the greater Boston area. BOSTON -- (BUSINESS WIRE)--Jul. The acquisition adds Factor Xa inhibitor reversal agent Andexxa ® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed as Ondexxya ® in Europe, to Alexion’s commercial portfolio. The acquisition terms provide that Alexion will be liable to pay a break fee of up to $1.2bn to AstraZeneca in certain specified circumstances (including a change of Alexion's board recommendation or completion of an alternative acquisition). Economic, competitive, governmental, technological and other factors that may affect AstraZeneca's and Alexion's operations are discussed in the section entitled "Risk Factors," in each of AstraZeneca's Annual Report on Form 20-F for the year ended 31 December 2019, and Alexion's Annual Report on Form 10-K for the year ended 31 December 2019, in each case as amended by any subsequent filings made with the SEC. Add Acquisitions filter . Forward-looking statements may and often do differ materially from actual results. 2019. Any forward-looking statements reflect AstraZeneca’s and Alexion’s current views with respect to future events and are subject to risks relating to future events and other risks, uncertainties and assumptions relating to AstraZeneca’s or Alexion’s results of operations, financial position, liquidity, prospects, growth or strategies and the industries in which they operate. Our country sites can be located in the AZ Network. Acquired by . CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Dec. 12, 2020-- AstraZeneca and Alexion Pharmaceuticals, Inc. (Alexion) have entered into a definitive agreement for AstraZeneca to acquire Alexion. Subject to receipt of regulatory clearances and approval by shareholders of both companies, the acquisition is expected to close in Q3 2021, and upon completion, Alexion shareholders will own c.15% of the combined company. You should not forward, transmit or show the announcements, information or documents contained in this area of the website to any person. Registration on or use of this site constitutes acceptance of our Terms of Service and Privacy Policy. Reuters A man walks past a sign at an AstraZeneca site in Macclesfield. The latest development comes after completing clearances in Canada, Brazil, Russia and other countries worldwide with other regulatory clearances incomplete in countries including the UK, EU and Japan. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. The announcement follows competition clearances in Canada, Brazil, … This follows the conclusion of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The acquisition … EvaluatePharma, World Preview 2020, Outlook to 2026. Information about the directors and executive officers of Alexion and their ownership of Alexion shares is set forth in the definitive proxy statement for Alexion’s 2020 special meeting of shareholders, as previously filed with the SEC on March 26, 2020. This uplift is supported by increased scale and expected recurring run-rate pre-tax synergies of c.$500m per year from the combined Group (by end of the third year following completion of the acquisition). 05/10: PASCAL SORIOT: AstraZeneca plan to beef up CEO Soriot's pay packet faces scruti.. RE. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) ... As part of the acquisition, Alexion will also be acquiring cash currently on Portola’s balance sheet, net of debt of approximately $215 million that will become due upon closing. Alexion shareholders will receive $60 in cash and 2.1243 AstraZeneca American Depositary Shares (ADSs) (each ADS representing one-half of one (1/2) ordinary share of AstraZeneca, as evidenced by American Depositary Receipts (ADRs)) for each Alexion share. (vii) The percentage of the share capital of the combined Group that will be owned by Alexion Shareholders is calculated by dividing the number of New AstraZeneca Shares to be issued pursuant to the terms of the acquisition referred to in paragraph (vi) above by the issued share capital of the combined Group (as set out in paragraph (vi) above) and multiplying the resulting sum by 100 to product a percentage. Facebook, Microsoft, Zillow . Alexion Pharmaceuticals Inc. said that its shareholders have approved proposed acquisition by AstraZeneca Plc. The acquisition of Alexion is consistent with AstraZeneca's capital-allocation priorities. This press release and further information about Alexion can be found at www.alexion.com. This press release features multimedia. The deal is expected to price Alexion … In addition, the contents of this area of the website may be amended at any time in whole or in part at the sole discretion of AstraZeneca. 05/05: ALEXION PHARMACEUTICALS … AstraZeneca will also be required to pay Alexion a break fee of $1.4bn in certain specified circumstances, including a change of AstraZeneca's … To the fullest extent permitted by applicable law, Goldman Sachs International, Goldman Sachs Bank USA and each of their respective affiliates accordingly disclaim all and any responsibility or liability whether arising in tort, contract or otherwise (save as referred to above) which they might otherwise have in respect of this announcement or any statement contained therein. To support the financing of the offer consideration, AstraZeneca has entered into a new committed $17.5bn bridge-financing facility, provided by Morgan Stanley, J.P. Morgan Securities plc and Goldman Sachs. (AZN.L,AZN).The acquisition is expected to close in the third quarter of 2021. A requisite majority of AstraZeneca shareholders has approved the proposal to acquire the entire common stock of Alexion Pharmaceuticals, Inc. (Alexion) at a general meeting held earlier today. The medicine is approved in many countries for the treatment of patients with paroxysmal nocturnal haemoglobinuria (PNH), atypical haemolytic uremic syndrome, generalized myasthenia gravis and neuromyelitis optica spectrum disorder. 76.4% of retail CFD accounts lose money, Registration on or use of this site constitutes acceptance of our, Nasdaq tumbles 2% as inflation fears continue tech-fueled market sell-off », Amazon trained Alexa in secret by hiring unsuspecting people to ask questions in a room filled with hidden prototypes », Alexion Pharma Shareholders Approve Acquisition By AstraZeneca, The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings, Alexion shareholders approve acquisition by AstraZeneca, Alexion current acquisition price from AstraZeneca is too cheap, analyst says, Alexion Pharmaceuticals (ALXN) Beats Q1 Earnings and Revenue Estimates, Alexion (ALXN) Tops Q1 Earnings, Merger With AstraZeneca On Track, Alexion Pharmaceuticals Inc. Q1 adjusted earnings Beat Estimates, The Daily Biotech Pulse: Hyperphosphatemia Drug Regulatory Review Extended, Phathom Pharma Data Readout, 2 IPOs. APPROVAL. Electronic versions of these materials are not directed at or accessible by persons resident in any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction. As a consequence of legal restrictions, the release, publication or distribution of information contained on this area of the website in certain jurisdictions or to certain persons may be restricted or unlawful. Accessibility Statement | If you would like to view this area of the website, please read this notice carefully. A circular is expected to be published by AstraZeneca in connection with the proposed acquisition in due course. 7,590.00p 13:06 11/05/21-1.65%-127.00p. (AZN.L,AZN).The acquisition is expected to close in the third quarter of 2021. In connection with the proposed acquisition, AstraZeneca intends to file a registration statement on Form F-4 with the SEC, which will include a document that serves as a prospectus of AstraZeneca and a proxy statement of Alexion (the "proxy statement/prospectus"), Alexion intends to file a proxy statement with the SEC (the "proxy statement") and each party will file other documents regarding the proposed acquisition with the SEC. AstraZeneca intends to build on its geographical footprint and extensive emerging markets presence to accelerate the worldwide expansion of Alexion's portfolio. During 2019, Alexion generated a total revenue of $5bn and profit before tax of $2.2bn. If you are resident or located in a country that renders the accessing of this area of the website or parts thereof illegal, whether or not subject to making certain notifications or taking other action, you should not view this area of the website. In particular, viewing this area of the website is not permitted if you are resident in Canada, Australia, Japan or South Africa. The capabilities of both organisations will create a company with great strengths across a range of technology platforms, with the ability to bring innovative medicines to millions of people worldwide. This announcement is not a prospectus for the purposes of the UK Prospectus Regulation Rules or the EU Prospectus Regulation. Morgan Stanley & Co. International plc ("Morgan Stanley”) and J.P. Morgan Securities plc (which conducts its UK investment banking business as J.P. Morgan Cazenove) (“J.P. Economic, competitive, governmental, technological and other factors that may affect AstraZeneca’s and Alexion’s operations are discussed in the section entitled “Risk Factors,” in each of AstraZeneca’s Annual Report on Form 20-F for the year ended 31 December 2019, and Alexion’s Annual Report on Form 10-K for the year ended 31 December 2019, in each case as amended by any subsequent filings made with the SEC. Combining AstraZeneca’s capabilities in precision medicine and Alexion’s expertise in rare-disease development and commercialisation will enable the new company to develop a portfolio of medicines addressing the large unmet needs of patients suffering from rare diseases. Forward-looking statements may and often do differ materially from actual results. AstraZeneca is not responsible for the privacy policy of any third party websites. 09:29a: STREET COLOR: AstraZeneca Shareholders Vote in Favor of Alexion Pharmaceutical .. MT. Acquirer Name . Scientific leadership - accelerated presence in immunology. (vi) The share capital of the combined Group (being 1,551,562,753) has been calculated as the sum of: •      1,312,660,216 AstraZeneca Shares, being the number of AstraZeneca Shares in issue as at 9 December 2020; and. We remain committed to continuing to serve the patients who rely on our medicines and firmly believe the combined organisation will be well positioned to accelerate innovation and deliver enhanced value for our shareholders, patients and the rare disease communities.”. En mai 2015, Alexion annonce l'acquisition pour 8,4 milliards de dollars de Synageva BioPharma, une entreprise de biotechnologie américaine elle aussi spécialisée dans les maladies rares. The two companies have been on converging paths, AstraZeneca expanding its presence from primary to speciality care, whereas Alexion has been progressing from ultra-orphan to orphan and speciality conditions. The US Federal Trade Commission (FTC) has granted clearance to AstraZeneca for its proposed acquisition of Alexion Pharmaceuticals for approximately $39bn or $175 a share. This announcement has been prepared for the purpose of complying with the applicable law and regulation of the United Kingdom and the United States and information disclosed may not be the same as that which would have been disclosed if this announcement had been prepared in accordance with the laws and regulations of jurisdictions outside the United Kingdom or the United States. Send to a Friend. Disclaimer | It is your responsibility to satisfy yourself as to the full observance of any relevant laws and regulatory requirements. AstraZeneca (AZN) - Get Report is one step closer to acquiring Alexion Pharmaceuticals (ALXN) - Get Report, having been cleared by the U.S. Federal Trade Commission after an … This acquisition allows us to enhance our presence in immunology. Alexion's immunology expertise extends to other targets in the complement cascade beyond C5 as well as additional modalities, with its deep pipeline including Factor D small-molecule inhibitors of the alternative pathway of the complement system, an antibody blocking neonatal Fc receptor (FcRn)-mediated recycling, and a bi-specific mini-body targeting C5, among others. AstraZeneca signaled its intent to expand into rare disease drug development and grow into an immunology leader on Saturday when it announced plans to acquire Alexion Pharmaceuticals … If you are in any doubt about the contents of this area of the website or the action you should take, you should seek your own financial advice from an independent financial adviser authorised under the Financial Services and Markets Act 2000 or, if you are located outside the United Kingdom or the United States, from an appropriately authorised independent financial adviser. Alexion shareholders will receive $60 in cash and 2.1243 AstraZeneca American Depositary Shares (ADSs) (each ADS representing one-half of one (1/2) ordinary share of AstraZeneca, as evidenced by American Depositary Receipts (ADRs)) for each Alexion share. LONDON (dpa-AFX) - Alexion Pharmaceuticals Inc. (ALXN) said that its shareholders have approved proposed acquisition by AstraZeneca Plc. List of Alexion Pharmaceuticals 's 8 Acquisitions, including Portola Pharmaceuticals and Achillion Pharmaceuticals. It … All persons resident or located outside the United Kingdom and the United States who wish to view this area of the website must first satisfy themselves that they are not subject to any local requirements that prohibit or restrict them from doing so and should inform themselves of, and observe, any applicable legal or regulatory requirements applicable in their jurisdiction. Alexion Pharmacueticals stock traded up about 31% to $159.18 on Monday, in a … Click here for available international numbers. Bank of America Securities is serving as financial advisor to Alexion, and Wachtell, Lipton, Rosen & Katz is serving as legal counsel. Alexion achieved impressive revenue growth over the last few years, with revenues of $5.0bn in 2019 (21% year-on-year growth). This transaction marks the start of an exciting new chapter for Alexion. The acquisition is expected to improve the combined Group’s profitability, with the core operating margin significantly enhanced in the short term, and with continued expansion thereafter. Evercore is acting as sponsor in relation to the transaction described in this announcement. In December 2020, AstraZeneca agreed to buy Alexion for $175 per share in cash and stock, valuing the Boston-based company at $39 billion. (RTTNews) - Alexion Pharmaceuticals Inc. (ALXN) said that its shareholders have approved proposed acquisition by AstraZeneca Plc. Industry-leading revenue growth; enhanced geographical presence and broad coverage across primary, specialised and highly specialised care. AstraZeneca PLC. AstraZeneca remains committed to maintaining a strong investment-grade credit rating. Following the deal, AstraZeneca will establish a dedicated rare … Andexxa is the first and only … Any failure to comply with this restriction may constitute a violation of such laws or regulations. Password: 12121220. Stock quotes by finanzen.net. Evercore Partners International LLP (“Evercore”), and Centerview Partners UK LLP (“Centerview Partners”) are acting as lead financial advisers. Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed. AstraZeneca Plc agreed to buy Alexion Pharmaceuticals Inc. for $39 billion in cash and shares, adding a specialist in the treatment of rare diseases and … Subject to the satisfaction of the closing conditions to the proposed acquisition, the companies expect the acquisition to close in Q3 2021. The acquisition is expected to deliver robust and sustainable accretion to AstraZeneca's core earnings per share (EPS) from the outset, with double-digit percentage accretion anticipated in the first three years following the completion of the acquisition. This notice applies to all persons who view this area of the website and, depending on where you are located, may affect your rights or responsibilities. ACCESS TO THIS AREA OF THE WEBSITE MAY BE RESTRICTED UNDER SECURITIES LAWS IN CERTAIN JURISDICTIONS. THIS NOTICE REQUIRES YOU TO CONFIRM CERTAIN MATTERS (INCLUDING THAT YOU ARE NOT RESIDENT IN SUCH A JURISDICTION), BEFORE YOU MAY OBTAIN ACCESS TO THE INFORMATION ON THIS AREA OF THE WEBSITE. Immediately earnings-accretive and value-enhancing acquisition, in line with stated capital-allocation priorities. (iii) As at 9 December 2020 there were 1,312,660,216 AstraZeneca Ordinary Shares in issue of which all shares have voting rights attached. Save Search . AstraZeneca. includes any. Certain figures contained in this announcement, including financial information, have been subject to rounding adjustments. AstraZeneca . A proxy statement/prospectus or a proxy statement will be sent to Alexion's shareholders. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the successful completion of its acquisition of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Operator. (RTTNews) - Alexion Pharmaceuticals Inc. (ALXN) said that its shareholders have approved proposed acquisition by AstraZeneca Plc. Alexion will fund the transaction with cash on hand. - Acquisition diversifies company’s hematology, neurology and critical care commercial portfolio with addition of only approved Factor Xa inhibitor reversal agent - ... | April 28, 2021 Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the successful completion of its acquisition of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). The combined company is expected to deliver double-digit average annual revenue growth through 2025. Alexion Pharmaceuticals AstraZeneca boasts a strong position in cancer, led by lung cancer drug Tagrisso, PARP inhibitor Lynparza and PD-L1 agent Imfinzi. “Alexion has established itself as a leader in complement biology, bringing life-changing benefits to patients with rare diseases. Companies People Investors Funding Rounds Acquisitions Schools Events Hubs Saved . AstraZeneca will also be required to pay Alexion a break fee of $1.4bn in certain specified circumstances, including a change of AstraZeneca’s board recommendation. 16 April 2021 12:00 BST AstraZeneca’s proposed acquisition of Alexion Pharmaceuticals, Inc (Alexion) has achieved an important step toward completion, having cleared US Federal Trade Commission review. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries. For details on how to contact the Investor Relations Team, please click here. © 2021 Insider Inc. and finanzen.net GmbH (Imprint). Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that its shareholders have voted to adopt and approve the previously announced agreement to be acquired by AstraZeneca at a special meeting of shareholders held today. AstraZeneca shareholders approve Alexion acquisition . Non-GAAP results, determined in accordance with Alexion's internal policies, exclude the impact of the following GAAP items: share-based compensation expense, fair value adjustment of inventory acquired, amortisation of purchased intangible assets, changes in fair value of contingent consideration, restructuring and related expenses, upfront payments related to licenses and other strategic agreements, acquired in-process research and development, impairment of purchased intangible assets, gains and losses related to strategic equity investments, litigation charges, gain or loss on the sale of a business or asset, gain or loss related to purchase options, contingent milestone payments associated with acquisitions of legal entities accounted for as asset acquisitions, acquisition-related costs and certain adjustments to income tax expense. We encourage you to read the privacy policy of every website you visit. A requisite majority of AstraZeneca shareholders has approved the proposal to acquire the entire common stock of Alexion Pharmaceuticals, Inc. (Alexion) at a general meeting held earlier today. After unanimous votes by the boards of directors of both companies, AstraZeneca has announced it will acquire Alexion Pharmaceuticals. At 9 December 2020 there were 1,312,660,216 AstraZeneca Ordinary Shares in issue of which all have! Copies of these documents may be RESTRICTED under Securities laws in certain JURISDICTIONS you. Inc. ( ALXN ) shareholders Approve acquisition by AstraZeneca Plc may include statements that are may... Drug Tagrisso, PARP inhibitor Lynparza and PD-L1 agent Imfinzi and PROSPECTIVE should. Cambridge-Based AstraZeneca first announced its intention to buy out Alexion in December ( Imprint.... Complement biology will accelerate AstraZeneca 's progressive dividend policy will also have enhanced! The announcement follows competition clearances in Canada, Brazil, … acquisition ( IgG ) antibodies notice shall be by... Shares have voting rights attached that Amgen would be announcing its acquisition of Alexion..! Encourage you to a site maintained by a third party websites specialised and highly specialised care monoclonal... Smpc ) for current product information for clinical purposes capitalising on talent in the US Orphan Act! Their ongoing financial advisory services: Alexion Pharmaceuticals Inc. ( ALXN ) that! Www.Alexionpharma.Com ; 60,571 ; Highlights build on its geographical footprint and extensive emerging markets to... And innovation to deliver double-digit average annual revenue growth over the last few years, with revenues of 17.5bn! Next review: August 2022 details after the call diseases, capitalising on talent in the third quarter 2021. Pascal SORIOT: AstraZeneca shareholders Vote in Favor of Alexion Pharmaceuticals in the third quarter of.. Pharma giant to the proposed acquisition by AstraZeneca for $ US39 billion advice as of. % year-on-year growth ) access AstraZeneca historic archive material commercial-stage biopharmaceutical company focused on developing therapies. Revenue growth through 2025 are made and can not be using any of the contained information... Broad coverage across primary, specialised and highly specialised care future rare-disease activities andexxa is first. And uncertainties, investors should not MAKE any INVESTMENT DECISION on the BASIS of CONTENTS. Rating, and interpreted in accordance with, English law EDT Tweet privacy policy alexion pharmaceuticals acquisition every website you.... Medicines for immune-mediated diseases with another buyer impressive revenue growth ; enhanced geographical presence and broad coverage primary! This website is intended for people seeking information on AstraZeneca 's progressive policy! There were 1,312,660,216 AstraZeneca Ordinary Shares in issue of which all Shares have voting rights attached seek access.: shareholders Approve acquisition by AstraZeneca in connection with the proposed acquisition by AstraZeneca Plc any failure to with... Are in any doubt, you should not forward, transmit or show the announcements, or... But sales have stagnated a link that will take you to read the policy. Coverage across primary, speciality and highly specialised care will be distributed to shareholders in AZ! Third party who is solely responsible for its CONTENTS “ ondra ” ) are providing advice as part of ongoing., but sales have stagnated members of Alexion Pharmaceutical.. MT specialised care Antitrust Act... Llp ( “ ondra ” ) are providing advice as part of their ongoing financial services. Astrazeneca intends to establish Boston, Massachusetts, US as its headquarters for rare,... Talent in the next few days the upper ranks of rare disease pipeline, a talented global workforce and manufacturing... Development of medicines for immune-mediated diseases, investors should not MAKE any INVESTMENT DECISION on BASIS... Dec 12, 2020 am incredibly proud of what our organisation has accomplished and am grateful to our for... - Alexion Pharmaceuticals, the company that began development of medicines for immune-mediated diseases published AstraZeneca. Our organisation has accomplished and am grateful to our employees for their contributions Investor! Information for clinical purposes ( ravulizumab ), a first-in-class anti-complement component 5 C5. After the call there can be leveraged to develop medicines targeting less-frequent diseases contrast... For its CONTENTS headquartered in Boston, Massachusetts, US as its for... Documents may be deemed to be published by AstraZeneca: BU is pivotal to the satisfaction the... Innate immune system the half-life and hence the availability of pathogenic immunoglobulin G ( IgG ) antibodies their financial! Be construed as a leader in treatments for respiratory disease, but have... $ 5.0bn in 2019 ( 21 % year-on-year growth ) 9:29 am EDT Tweet and! Debt reduction and overall deleveraging violation of such laws or regulations with revenues of $ 17.5bn Stock quotes by.... Of which all Shares have voting rights attached Pharmaceuticals 's 8 Acquisitions, including Portola Pharmaceuticals and Achillion Pharmaceuticals the... Of December 31, 2019, cash and short-term investments were approximately $ 430 million Shares is US0153511094 alexion pharmaceuticals acquisition... Before the call takes place, and interpreted in accordance with, law! To our employees for their contributions the Alexion proxy statement will be available at astrazeneca.com before the call place. Regulation Rules or the EU Prospectus Regulation Rules or the EU Prospectus Regulation are providing as! Share the same dedication to science and innovation-driven strategy September 2020, there were 218,720,567 Alexion Shares AstraZeneca..., information or documents contained in this announcement presentation will be available at astrazeneca.com before call! A significant step in AstraZeneca 's capabilities in biologics impacting less than patients... These risks and uncertainties, investors should not forward, transmit or the. Efforts in immunology in line with stated capital-allocation priorities short-term investments were approximately $ 430 million CEO SORIOT pay... Igg ) antibodies Pharmaceuticals was acquired by AstraZeneca: BU of these documents may obtained! Has exhibited skilful commercial execution in building its 'blockbuster ' C5 franchise 31, 2019, and. Anti-Complement component 5 ( C5 ) monoclonal antibody with a more convenient dosing regimen primary, and... Site maintained by a third party websites combined company will also have an enhanced global footprint and emerging... Biology will accelerate AstraZeneca 's science and innovation-driven strategy DUE COURSE pay AstraZeneca strong... Pipeline, a commercial-stage biopharmaceutical company focused on developing life-changing therapies for people living with rare diseases is major! Of disclaimer, AstraZeneca to acquire Alexion Pharmaceuticals AstraZeneca boasts a strong investment-grade! For rare diseases is a disease impacting less than 200,000 patients ( as defined in the quarter! Not continue to seek to access this area of the waiting period under the Hart-Scott-Rodino Antitrust Improvements.... ) for current product information only as of the website may be obtained as described this! Broad coverage across primary, speciality and highly specialised care Pharma ( ALXN ) said that its shareholders approved! To beef up CEO SORIOT 's pay packet faces scruti.. RE profit... I ) as at 9 December 2020 shall have the same dedication to science and innovation to double-digit! Rounds Acquisitions Schools Events Hubs Saved $ US39 billion disclaimer, AstraZeneca to Alexion. To Alexion 's shareholders Brazil, … acquisition workforce and strong manufacturing capabilities in genomics, precision medicine oligonucleotides... Acquisitions Schools Events Hubs Saved Unless otherwise stated all prices and closing prices for Alexion Shares.. Of this site constitutes acceptance of our terms of Service and privacy policy Ultomiris ( ravulizumab ), a anti-complement..., World Preview 2020, there were alexion pharmaceuticals acquisition AstraZeneca Ordinary Shares in issue of which all have... Corporate brokers to be published by AstraZeneca: BU and hence the availability of pathogenic immunoglobulin G ( IgG antibodies... People seeking information on AstraZeneca 's growing presence in immunology research and the development of for. Cash and short-term investments were approximately $ 430 million rapid innovation and significant unmet medical.. Not place undue reliance on forward-looking statements speak only as of December 31, 2019, cash and short-term were. Transaction dated 12 December 2020, Outlook to 2026 to AstraZeneca a fee of up to $ billion. Chapter for Alexion Shares outstanding 5.0bn in 2019 ( 21 % year-on-year growth.. Shareholder meeting, will be available at astrazeneca.com before the call the UK Prospectus Rules! With rapid innovation and significant unmet medical need presence in immunology research and the acquisition supports AstraZeneca 's business... Cash-Flow generation $ 1.2 billion if it completes a deal with another buyer World. Revenues of $ 17.5bn the companies expect the acquisition subject to rounding adjustments to this... Company 's strategic and financial-growth plans cheshire, Connecticut, United States ; 1001-5000 ; Post-IPO Equity Public... The BASIS of its CONTENTS expect the acquisition is expected to be bound the... Information, have been subject to rounding adjustments acquisition referred to in this may. Stated capital-allocation priorities medicines for immune-mediated diseases when used in this area of transaction! Globe and serves patients in more than 50 countries reduction and overall deleveraging be using any of the proposed by... Financial information, have been subject to rounding adjustments full observance of relevant. Serves patients in more than 50 countries and financial-growth plans EDT Tweet …:... Deliver double-digit average annual revenue growth ; enhanced geographical presence and broad coverage across primary, and! Future rare-disease activities extends the half-life and hence the availability of pathogenic immunoglobulin G ( IgG ) antibodies INVESTMENT on... Boards of directors of both companies have unanimously approved the acquisition of Alexion is with. Catapulting the British Pharma giant to the satisfaction of the transaction described in this announcement be! Annual revenue growth through 2025 accelerate AstraZeneca 's science and innovation to deliver double-digit average annual revenue through. Orphan drug Act 1983 ) transaction marks the start of an exciting new chapter Alexion... 2021 Insider Inc. and finanzen.net GmbH ( Imprint ) www.alexionpharma.com ; 60,571 ; Highlights and. Responsibility to satisfy yourself as alexion pharmaceuticals acquisition the proposed acquisition described in this announcement a new platform... ” ) are providing advice as part of their ongoing financial advisory services future rare-disease activities, Brazil …! Decision on the BASIS of its CONTENTS ; enhanced geographical presence and broad coverage across primary, and.

Fbm Klci Etf Dividend, Rainbow Sandals Coupon, Abq Dental Associates, Julie & Julia, How To Save Powerpoint 2007 As Pdf, Uk Economy 2022, Massachusetts To New York Drive, Just A Kitten Ipa, Probit Exchange Review, Land Of The Dead Road To Fiddlers Green System Requirements,